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Abstract
Background and Aim: An abnormal immune response to intestinal bacteria has been
observed in Crohn’s disease (CD). Clostridium difﬁcile infection incidence and sever-
ity are increased in CD, but reports on the humoral response have provided conﬂicting
results. We aimed to shed light on the possible role of C. difﬁcile in CD pathogenesis
by paying attention to the inﬂuence of immunomodulatory treatment on the humoral
response.
Methods: A total of 71 consecutive outpatients with CD, 67 with ulcerative colitis
(UC), and 121 healthy controls were analyzed for serum IgA and IgG to C. difﬁcile
toxins A and B.
Results: IgA levels were similar in all study groups. IgG to toxin A was increased
similarly in CD and UC (P = 0.02 for both). In contrast, IgG to toxin B was elevated
only in CD patients not receiving disease-modifying anti-inﬂammatory bowel disease
drugs (DMAID) (n = 16) (P = 0.0001), while the CD medication subgroup (n = 47)
had a level similar to healthy controls. The UC results were not inﬂuenced by
DMAID treatment.
Conclusion: Our ﬁndings add support to the idea of a disturbed interaction between
intestinal cells and the microbiota being part of the CD disease mechanism. An abnor-
mal immune response to C. difﬁcile toxin B may be a critical component of this
interaction.
Introduction
Clostridium difﬁcile is an anaerobic bacterium that can be part of
the normal intestinal ﬂora, but with pathogenic strains producing
the two major exotoxins, toxin A and toxin B, with each being
capable of mediating infection.1–4 Patients with inﬂammatory
bowel disease (IBD), including Crohn’s disease (CD) and ulcera-
tive colitis (UC), have an increased risk of developing C. difﬁcile
infection5 and asymptomatic colonization.6 An excess of antibi-
otic use in the early childhood of IBD patients has been
reported7; this may be causally related to the overrepresentation
of C. difﬁcile, perhaps indirectly via an altered gut microbiota,
losing its protective role against C. difﬁcile expansion.8
Serum IgG antibodies against these toxins are protective
in humans.2,9 The ﬁrst report on the antibody response to
C. difﬁcile in IBD was limited to the analysis of IgG to toxin B
and noted an increased level with a tendency to be most marked
in CD.10 A few IBD patients were included in a cystic ﬁbrosis
study, with a tendency for IgG to toxin A, but not to toxin B, to
become generated during ongoing C. difﬁcile infection.11
Another study failed to demonstrate any increase in antitoxin
IgG due to C. difﬁcile infection in IBD patients.12 Several factors
may have contributed to these discrepant observations, such as
patient characteristics involving remission, relapse, C. difﬁcile
infection (prior or ongoing), IBD treatment types, previous intes-
tinal resection, and control subject characteristics as well as
enzyme-linked immunosorbent assay (ELISA) methodology.
However, anti-tumor necrosis factor (anti-TNF) treatment has
been shown not to be associated with an excess of C. difﬁcile
infection13, although it does mediate a lowered humoral response
to hepatitis B vaccine expansion.14 The present study is an
attempt to shed more light on C. difﬁcile seroreactivity in IBD by
paying attention to the possible inﬂuence of immunomodulatory
treatment and by applying the previously well-documented9
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ELISA method to relatively large IBD outpatient material. The
results may increase our understanding of IBD pathogenesis and
aid in identifying effective monoclonal antibodies to C. difﬁcile
toxins for treatment.15
Methods
Patients and healthy controls. This is a prospective
study on outpatients, primarily with scheduled visits, at three
clinics in southern Sweden specialized in IBD. The study was
approved by the local medical ethics committee of Lund Univer-
sity (permit number LU 552-03), and written informed consent
was obtained from all patients.
Sera from 138 consecutive patients with established IBD
(76 females and 62 males, aged 18–82 years; mean 45 years),
including 71 with CD (45 females and 26 males, aged
18–78 years; mean 43 years) and 67 with UC (31 females and
36 males, aged 19–82 years; mean 47 years), were analyzed.
Data on disease duration, previous intestinal resection, smoking
habits, and frequency as reported by the patients during the
recent year of all types of infections are listed in Table 1. The
indicated type of treatment was ongoing at the time of inclusion
in the study and sampling of serum (shown in Table 2). Disease-
modifying anti-IBD drugs are referred to by us as DMAID. The
panel of controls was composed of 121 randomly selected sera
from healthy blood donors (51 females and 70 males, aged
20–66 years; mean 45 years) and was obtained from the South-
ern Sweden Microbiology Biobank.
Antibody analysis. Patient and healthy control sera were
stored at −20C until analysis. Levels of serum antibodies
against toxins A and B were measured in doublets by ELISA as
previously described7 with minor modiﬁcations, using 96-well
polystyrene microtiter plates coated with either toxin A or toxin
B and mouse monoclonal antibodies to toxin A and toxin B,
respectively, serving as positive controls (tgcBIOMICS, Mainz,
Germany). Patient sera were diluted 1:800 for analysis of IgA
and 1:1600 for IgG. Secondary antibodies were horseradish
peroxidase-conjugated. One patient serum used in our previous
studies was included on each plate as an additional and
manufacturer-unrelated control.
Statistics. Antibody measurement data were not normally dis-
tributed; the analyses were performed using the Mann–Whitney
U test. As is common practice, we call the ﬁnding statistically
signiﬁcant if the relevant P-value is lower than 0.05. All statisti-
cal analysis is performed as described in the reference
literature.16
Results
Serum IgG to toxin A was found to be increased in the IBD
patients to a similar extent in CD and UC (P = 0.02, as compared
to healthy controls), with ELISA median values 1.41 for CD,
1.51 for UC, and 1.24 for healthy controls (Fig. 1a). IgG to toxin
B was elevated signiﬁcantly among the CD patients (P = 0.002,
as compared to healthy controls) and somewhat among UC
(P = 0.06, as compared to healthy controls); the median for CD
was 1.54, for UC 1.36, and for the healthy controls 1.21
(Fig. 1b). The IgA results showed very similar medians for all
three subject groups (for toxin A 0.55–0.60 and for toxin B
0.26–0.31), with no signiﬁcance (results not shown).
We sought to determine if the observed IgG elevation
among IBD patients was inﬂuenced by DMAID treatment. A
Table 1 Patient characteristics
CD no DMAID CD DMAID UC no DMAID UC DMAID Healthy controls
Female/male (n) 11/5 29/18 10/15 12/14 51/70
Age < 45 years (n, %)† 7, 44 29, 62 9, 36 11, 42 60, 50
Disease duration
≥10 years (n, %)† 6, 38 24, 51 10, 43‡ 11, 42 NA
Intestinal resection (n, %)† 11, 69 24, 51 0 1, 4 NA
Smokers (n, %)† 2, 13§ 15, 33§ 7, 28 1, 4 ND
Infections >1 per year (n, %)† 10, 71‡ 35, 74 12, 48 11, 42 ND
†There was no signiﬁcant difference in frequency between the disease-modifying anti-inﬂammatory bowel disease drugs (DMAID) and the no
DMAID groups.
‡Information is lacking in two patients.
§Information is lacking in one patient.
CD, Crohn’s disease; UC, ulcerative colitis; NA, not applicable; ND, no data.
Table 2 DMAID data
CD UC
Total patients 71 (100%) 67 (100%)
No data on DMAID 8 (11%) 16 (24%)
DMAID-treated 47 (66%) 26 (39%)
Azathioprine, total 42 (89%†) 12 (46%†)
Only azathioprine 31 9
+ TNF inhibitor 10 1
+ Mesalazine 1 2
TNF inhibitor, total 12 (26%†) 2 (8%†)
only TNF inhibitor 2 1
+ Azathioprine 10 1
Mesalazine, total 3 (6%†) 15 (58%†)
Only mesalazine 2 13
+ azathioprine 1 2
Methotrexate 1 0
†% of DMAID-treated patients.
The data shown are: n (%).
CD, Crohn’s disease; TNF, tumor necrosis factor; UC, ulcerative colitis.
G Henriksson et al. Seroreactivity to Clostridium difﬁcile in IBD
JGH Open: An open access journal of gastroenterology and hepatology 3 (2019) 154–158
© 2018 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.
155
majority of the CD patients (47/71; 66%) and a smaller fraction
among UC (26/67; 39%) were treated with at least one type of
DMAID (Table 2); these ﬁgures may represent an underestimate
because we lack information on treatment status for 8 patients
with CD and 16 with UC. Azathioprine and TNF inhibitors dom-
inated in CD and mesalazines and azathioprine in UC.
There was no correlation between treatment and IgG to
toxin A in either CD or UC (results not shown). There was a
trend, but with no signiﬁcance, for a higher IgG to toxin B in
UC patients treated with DMAID compared with the UC sub-
group with no such drug (Fig. 2). Among UC patients with a
mesalazine as the only DMAID drug (13 of all 26 DMAID-
treated UC), there was also a nonsigniﬁcantly higher level of IgG
to toxin B, and there was no signiﬁcant difference between
untreated UC and all DMAID UC or with DMAID except mesa-
lazine. However, while CD patients not receiving medication had
a most marked elevation of IgG to toxin B compared with
healthy controls (P = 0.0001), the CD patients taking DMAID
presented with a normal level; medians were 1.99, 1.21, and
1.35, respectively (Fig. 2). There were 2 CD patients taking
mesalazine as the only DMAID type, precluding a meaningful
evaluation of the effect of this drug among all 47 DMAID-treated
CD patients. We analyzed if the different levels of IgG to toxin
B between treated and untreated CD patients could be attributed
to a single type of DMAID, but no statistical signiﬁcance due to
any of the DMAID types (listed in Table 2) was found (as all but
ﬁve DMAID-treated patients had azathioprine and only three had
mesalazine, it was statistically meaningful only to note a slight
trend (P = 0.22) for higher IgG to toxin B in patients with TNF
inhibitors compared with DMAID except TNF inhibition).
There was no signiﬁcant difference among DMAID-treated
CD patients regarding the presence of the potentially confounding
factors listed in Table 1: patient age, disease duration, intestinal
resection, smoking habits, or number of infections.
Discussion
Both the incidence and severity of C. difﬁcile infection have
increased dramatically in the general population during the past
two decades4, and there has been an even higher increase among
patients with IBD.5 The humoral immune response to the
C. difﬁcile toxins A and B is known to be protective in
humans,2,9 but previous reports on seroreactivity to C. difﬁcile in
IBD patients have provided conﬂicting results.10–12 In summary,
we found IgA levels in IBD to be no different from healthy con-
trols but IgG to toxin A to be elevated similarly in both CD and
UC and IgG to toxin B to be elevated only in CD. Our ﬁndings
are in agreement with Shakir et al.,10 who reported that IBD
patients have a higher level of IgG to toxin B than non-IBD con-
trol subjects, probably including a higher level in CD than in UC
(there were no statistical data). Findings differing from ours may
be attributed to inclusion of subjects with ongoing or recent
C. difﬁcile infection. Hughes et al.12 observed elevated IgA to
both toxins in patients with infection and no IgG abnormalities
in IBD; a strength of this study is more detailed clinical informa-
tion than in our material, including ruling out a signiﬁcant differ-
ence in antibiotic use during the prior 6 months between IBD
patients and healthy controls. A study focusing on cystic ﬁbrosis
found a small number of IBD patients (3 CD and 7 UC) with
ongoing C. difﬁcile infection to have a trend suggesting high IgG
to toxin A but low IgG to toxin B (IgA was not analyzed).11
We interpret our ﬁnding in CD and UC of a high level of
IgG to toxin A to reﬂect a memory of a normal immune response
to C. difﬁcile infection, agreeing well with C. difﬁcile infection
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Figure 1 IgG to Clostridium difﬁcile toxins A and B. Enzyme-linked immunosorbent assay arbitrary spectrophotometric absorbance unit median
values are shown. Boxes represent values between quartiles 1 and 3, and a thick line indicates the median. Whiskers show the max and min values
located above the top or below the bottom of the box, respectively, within a 1.5 interquartile distance. Circles denote outliers values located outside
a 1.5 interquartile distance. CD, Crohn’s disease; UC, ulcerative colitis.
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being more common in IBD than in non-IBD controls. Next, we
consider our most striking ﬁnding, namely, a highly signiﬁcantly
(P = 0.0001) elevated level of IgG to toxin B among CD patients
without immunomodulatory DMAID treatment, coupled with a
normal level among the DMAID-treated CD subgroup.
How should the different response to toxin B between
treated and untreated CD patients be interpreted? Is it because of
the medication per se or the therapeutic effects on disease activ-
ity? We cannot conclude an answer, but because there was no
difference in IgG to toxin B between the types of DMAID, we
speculate that an effect of a drug itself is unlikely. Although it
seems plausible that the intestinal pathology typical for CD, with
deeper intestinal wall layers rich in immune cells involved com-
pared with UC, would lead to more heavy exposure to C. difﬁcile
antigen, the remarkably high level of IgG to toxin B in CD
patients not receiving DMAID remains to be explained because
we ﬁnd it unlikely that only one of the two toxins, namely,
toxin B, will reach into deeper layers. Instead of heavy exposure
of intestinal immune cells to C. difﬁcile antigens, we propose that
an abnormal immune response to toxin B is involved.
Considering the seemingly endless complexity of the
intestinal immune system, interacting dynamically with luminal
antigens and recently shown to include mucosa-resident T cell-
dependent memory B cells, it is possible that a heightened IgG
reactivity with toxin B, persisting after infection, may be part of
an abnormal immune response in CD.8,17 Our proposition closely
follows the suggestions made in a report showing enhanced
development in CD of IgG against many intestinal commensal
bacteria, leading the authors to conclude that there is a general-
ized increased IgG response to the intestinal microbiota, with no
speciﬁc species being involved in CD pathogenesis.18 However,
our ﬁnding of markedly different reactivity to two separate toxins
from the same species serves as an indicator that, amid a back-
ground of a generalized hyperreactivity, there may be bacterial
factors playing a role in CD pathogenesis.
Assuming that an abnormal immune response in CD is
mediating the strong production of IgG to toxin B, then can anal-
ysis of this IgG possibly be an early diagnostic marker? It might
be a more efﬁcient marker, one that is more readily analyzed on
a routine basis, than the fecal microbiome pattern suggested to
be a potential early disease marker in CD.19 Such a diagnostic
tool is needed because it is now acknowledged that DMAID
treatment of IBD should ideally be initiated already before the
bowel has become severely damaged.20,21
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